Neurocritical Care

, Volume 16, Issue 2, pp 299–305 | Cite as

Early Ketamine to Treat Refractory Status Epilepticus

Practical Pearl



Management of refractory status epilepticus (SE) involves administration of intravenous γ-aminobutyric acid (GABAA) receptor agonists, such as benzodiazepines, barbiturates, or propofol. Animal models suggest that reductions in synaptic GABAA receptors may cause these drugs to become less effective as the duration of SE increases. This may explain the large doses that are commonly required to control seizures, which in turn contributes to a high incidence of complications, including hypotension and the need for vasopressors. In contrast, expression of excitatory N-methyl-d-aspartate (NMDA) receptors increases with prolonged SE and their stimulation by glutamate may propagate seizure activity. Ketamine is a NMDA-receptor antagonist that is considered promising as treatment for refractory SE. Compared with other anaesthetic drugs, ketamine produces less hypotension.


This report describes a patient who developed worsening hypotension with escalating doses of midazolam and propofol in the context of non-convulsive SE. He was therefore treated with ketamine within hours of being diagnosed.


Ketamine was immediately efficacious at reducing the frequency, amplitude, and duration of seizures. The dose was rapidly titrated upwards using quantitative continuous EEG monitoring, until seizures were completely abolished. SE did not recur with weaning of sedatives and he went on to have an excellent recovery. A small number of previous reports have found ketamine to abort late SE. In most cases, ketamine was administered several days into the course, and outcomes were poor even though seizures were controlled.


Larger series and phase I clinical trial(s) of ketamine for treatment of refractory SE seem warranted.


Status epilepticus Seizure Shock Hypotension Ketamine Sedation 



The author acknowledges Dr. Neelan Pillay, who assisted with timely cEEG interpretation in this patient.


  1. 1.
    Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10:922–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Claassen J, Hiersch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43:146–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Goodkin HP, Yeh JL, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurol. 2005;25:5511–20.Google Scholar
  4. 4.
    Mazarati AM, Wasterlain CG. N-methyl-d-aspartate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett. 1999;265:187–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Kapur J, Lothman EW. NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures. Epilepsy Res. 1990;5:103–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42:117–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Walker MC, Howard RS, Smith SJ, et al. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. Q J Med. 1996;89:913–20.Google Scholar
  8. 8.
    Kofke WA, Bloom MJ, Van Cott A, Brenner RP. Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesthesiol. 1997;9:269–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51:1765–6.PubMedGoogle Scholar
  10. 10.
    Nathan B, Smith TL, Bleck TB. The use of ketamine in the treatment of refractory status epilepticus. Neurology. 2002;3:A197.Google Scholar
  11. 11.
    Ubogu EE, Sagar SM, Lerner AJ, et al. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav. 2003;4:70–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82:219–22.PubMedCrossRefGoogle Scholar
  13. 13.
    Hsieh CY, Sung PS, Tsai JJ, Huang CW. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharm. 2010;33:165–7.CrossRefGoogle Scholar
  14. 14.
    Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure. 2011;20:723–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Stewart CP, Otsubo H, Ochi A, et al. Seizure identification in the ICU using quantitative EEG displays. Neurology. 2010;75:1501–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Ko SB, Ortega-Gutierrez S, Choi HA, et al. Status epilepticus-induced hyperemia and brain tissue hypoxia after cardiac arrest. Arch Neurol. 2011;68:1323–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Stewart LS, Persinger MA. Ketamine prevents learning impairment when administered immediately after status epilepticus onset. Epilepsy Behav. 2001;2:585–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Martin BS, Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia. 2008;49:248–55.PubMedCrossRefGoogle Scholar
  19. 19.
    Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37:3024–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia. 2004;45:757–63.PubMedCrossRefGoogle Scholar
  21. 21.
    Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29:1417–25.PubMedCrossRefGoogle Scholar
  22. 22.
    Mewasingh LD, Skhara T, Aeby A, et al. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure. 2003;12:483–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Kramer U, Shorer Z, Ben-Zeev B, et al. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol. 2005;20:184–7.PubMedGoogle Scholar
  24. 24.
    Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly be reversed uptake. Nature. 2000;403:316–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Benarroch EE. NMDA receptors: recent insights and clinical correlations. Neurology. 2011;76:1750–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Critical Care MedicineUniversity of CalgaryCalgaryCanada
  2. 2.Department of Clinical NeurosciencesUniversity of CalgaryCalgaryCanada

Personalised recommendations